Therapies Reducing Adverse Events in Extensive-Stage SCLC

In ES-SCLC, Oncologists Often Get Ahead of Formal Risk Categories to Prevent Febrile Neutropenia

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead of formal risk stratification.

Multilineage Cytopenias, Not Neutropenia Alone, Are Driving Interest in Trilaciclib for ES-SCLC

During an event, Julia Rotow, MD, and participants discussed how a real-world case of cascading anemia and thrombocytopenia shifted the group's thinking on multilineage prophylaxis for extensive-stage small cell lung cancer.

Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC

During a live event, Julia Rotow, MD, and participants discussed how community oncologists are managing chemotherapy-induced neutropenia in extensive-stage small cell lung cancer.

Navigating Myelosuppression in Small Cell Lung Cancer

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and safety notes.

Managing Chemotherapy-Induced Myelosuppression in Small Cell Lung Cancer

Mohamed K. Mohamed, MD, PhD, discusses how CIM disrupts treatment, burdens patients, and why a proactive management approach is critical in SCLC care.

CDK4/6 Inhibition Preserves Multiple Cell Lines in SCLC

Martin F. Dietrich, MD, PhD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.

Reducing Chemotherapy Toxicity Using Trilaciclib in SCLC

During a live event, Misty D. Shields, MD, PhD, discusses how trilaciclib reduces myelosuppression and other complications in small cell lung cancer.

Managing Chemotherapy-Induced Neutropenia in SCLC

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced neutropenia in SCLC.